7 completed, 4 active not recruiting, 3 terminated, 2 withdrawn. 18 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 7, Active not recruiting 4, Terminated 3, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Terminated 2, Withdrawn 1 |
Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo, SHINGRIX - Varicella-zoster Virus | Phase 1 | Active not recruiting | Suzhou Abogen Biosciences Co., Ltd. | 180 | 2025-05-27 | 2026-05-11 |
| Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ) | Phase 1 | Recruiting | Guangzhou Patronus Biotech Co., Ltd. | 92 | 2025-03-13 | 2025-04-01 |
| Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years EuHZV, Shingrix - Varicella Zoster Virus Infection, Herpes Zoster | Phase 1 | Active not recruiting | EuBiologics Co.,Ltd | 72 | 2024-07-15 | 2025-06-17 |
| A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants HZ Vaccine (IN001), Placebo, Shingrix - Herpes Zoster | Phase 1 | Completed | Shenzhen Shenxin Biotechnology Co., Ltd | 150 | 2024-07-05 | 2026-03-31 |
| A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years LYB004 25µg, LYB004 50µg, SHINGRIX - Herpes Zoster | Phase 1 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 48 | 2024-03-27 | 2025-03-13 |
| A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV - Herpes Zoster | Phase 1 | Completed | CanSino Biologics Inc. | 65 | 2023-11-07 | 2024-12-04 |
| A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy TNM005, Placebo, VariZIG - Varicella | Phase 1 | Unknown | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 48 | 2023-09-12 | 2024-07-11 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children Investigational live attenuated varicella vaccine, control live attenuated varicella vaccine, diluent of lyophilized vaccine - Varicella | Phase 1 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 270 | 2016-04-01 | 2017-10-26 |
| Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults MG1111, VARIVAX - Varicella (Chicken Pox) | Phase 1 | Completed | Green Cross Corporation | 39 | 2015-03-01 | 2017-04-27 |
| iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma GD2 T cells, VZV vaccine, Fludarabine - Osteosarcoma, Neuroblastoma | Phase 1 | Active not recruiting | Baylor College of Medicine | 26 | 2014-04-01 | 2026-04-22 |
| Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study Zostavax - Herpes Zoster | Phase 1 / Phase 2 | Withdrawn | University of Zurich | 2010-12-01 | 2013-03-01 | |
| Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Varicella Zoster Virus Vaccine (Zostavax) - Immunosenescence, Shingles | Phase 1 | Completed | University of Colorado, Denver | 33 | 2010-11-01 | 2021-06-25 |
| Immune Responses to Two Dose Varivax +/- MMR-II MMR-II, Pro-Quad, Varivax - Measles, Mumps | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 105 | 2005-10-01 | 2010-08-27 |
| Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients Varivax® - Kidney Transplant Recipients | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 1998-02-01 | 2017-02-16 |
| Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox Varicella Virus Vaccine (Live) - HIV Infections, Chickenpox | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2021-11-01 | |
| A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children Varicella Virus Vaccine (Live) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2021-10-29 | |
| The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children Valacyclovir hydrochloride - Herpes Simplex, HIV Infections | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-04 |
Herpes Zoster (9) · HIV Infections (3) · AIDS-Related Complex (2) · Varicella Zoster Virus Infection (2) · AIDS-Related Opportunistic Infections (1) · Acquired Immunodeficiency Syndrome (1) · DNA Virus Infections (1) · Herpes Simplex (1) · Herpesviridae Infections (1) · Infections (1) · Measles (1) · Mumps (1) · Neuroblastoma (1) · Osteosarcoma (1)
DNA Virus Infections (17) · Herpesviridae Infections (17) · Infections (17) · Virus Diseases (17) · Varicella Zoster Virus Infection (16) · RNA Virus Infections (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · Lentivirus Infections (3) · Retroviridae Infections (3) · Sexually Transmitted Diseases (3) · Sexually Transmitted Diseases, Viral (3)
Herpes Zoster Vaccine (5) · Chickenpox Vaccine (3) · Antigens (1) · Cyclophosphamide (1) · Injections (1) · Suspensions (1) · Valacyclovir (1) · fludarabine (1) · fludarabine phosphate (1) · varicella-zoster immune globulin (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Guangzhou Patronus Biotech Co., Ltd. (2) · Baylor College of Medicine (1) · CanSino Biologics Inc. (1) · EuBiologics Co.,Ltd (1) · Green Cross Corporation (1) · Pfizer (1) · Shenzhen Shenxin Biotechnology Co., Ltd (1) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (1) · Suzhou Abogen Biosciences Co., Ltd. (1) · University of Colorado, Denver (1) · University of Zurich (1) · Zhuhai Trinomab Pharmaceutical Co., Ltd. (1)
United States (9) · China (3) · Australia (2) · Canada (1) · South Korea (1)
Adit A Ginde, MD, MPH (1) · Ahad Sabet, MD (1) · Amir Tejani, MD (1) · Anne A Gershon (1) · Anne Gershon (1) · Barbara Hasse, MD (1) · Beverly L. Connelly, MD (1) · Bryson Y (1) · Christina Chang, M.D (1) · Cliona Rooney, PhD (1) · Gershon A (1) · Keller MA (1) · Lisa L Wang, MD (1) · Myron J Levin (1)
K23AG040708 (1), P01CA094237 (1)